AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sarepta Therapeutics faces class action lawsuit over securities fraud allegations.
ByAinvest
Saturday, Jul 12, 2025 10:02 am ET1min read
Sarepta Therapeutics is facing a class action lawsuit alleging securities fraud and unlawful business practices. The lawsuit was filed by Pomerantz LLP and concerns the death of a young patient who participated in a clinical trial for Sarepta's gene therapy treatment. Investors who purchased or acquired Sarepta securities between March 18, 2021, and March 18, 2022, have until August 25, 2022, to ask the court to appoint them as lead plaintiff. A copy of the complaint can be obtained at www.pomerantzlaw.com.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is facing a class action lawsuit alleging securities fraud and unlawful business practices. The lawsuit was filed by Pomerantz LLP and concerns the death of a young patient who participated in a clinical trial for Sarepta's gene therapy treatment, ELEVIDYS [2]. The complaint alleges that the company made false and misleading statements about the safety profile, clinical development, and commercial prospects of ELEVIDYS [2].The lawsuit specifically targets the period between June 22, 2023, and June 24, 2025 [1]. During this time, Sarepta disclosed several adverse events related to ELEVIDYS, including the death of two patients due to acute liver failure [1]. These disclosures led to significant declines in Sarepta's stock price, with shares dropping 27.44% on March 18, 2025, 7.13% on April 4, 2025, 42.12% on June 15, 2025, and 8.01% on June 24, 2025 [2].
Investors who purchased or acquired Sarepta securities during the relevant time frame are encouraged to contact Pomerantz LLP to learn more about the class action lawsuit and the opportunity to participate [2]. The deadline to ask the court to appoint a lead plaintiff is August 25, 2025 [1, 2].
References:
[1] https://www.globenewswire.com/news-release/2025/07/11/3114259/3080/en/Lost-Money-on-Sarepta-Therapeutics-Inc-SRPT-Join-Class-Action-Suit-Seeking-Recovery-Contact-Levi-Korsinsky.html
[2] https://www.marketscreener.com/quote/stock/SAREPTA-THERAPEUTICS-INC-11204214/news/Pomerantz-Law-Firm-Reminds-Investors-with-Losses-on-their-Investment-in-Sarepta-Therapeutics-Inc-o-50450410/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet